Russia's Sputnik V Rises to 2nd Place in Terms of Countries' Approvals

The producer of the vaccine took to Twitter to announce the news.

​The AstraZeneca vaccine is currently ranked first in the world in terms of the number of approvals, licensed in 49 countries, followed by Sputnik V with 45. Pfizer is ranked third with 43, followed by Moderna (19 countries), as well as three Chinese vaccines — Sinopharm (18), Sinovac (16), CanSino (4). The Johnson&Johnson vaccine ranks eighth, it was approved by 4 countries. 

Currently, the use of the Sputnik V vaccine is approved in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, the United Arab Emirates, Iran, the Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (part of Bosnia and Herzegovina), Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San Marino, Ghana, Syria, Kyrgyzstan, Guyana, Egypt, Honduras, Guatemala, Moldova, Slovakia, Angola, Djibouti, the Republic of the Congo, Sri Lanka, Laos and Iraq.

The total population of 45 countries where the Sputnik V vaccine is registered exceeds 1.2 billion.

Kirill Dmitriev, the CEO of the Russian Direct Investment Fund (RDIF), which is promoting Russia’s Sputnik V vaccine in foreign markets, said earlier that confidence in the vaccine is growing, since it has no side effects and does not provoke allergies. Sputnik V, developed by the Gamaleya Epidemiology and Microbiology Centre and registered by the Russian Ministry of Health on 11 August, was the world's first vaccine against the novel coronavirus. The vaccine is based on the well-studied human adenovirus vector platform, and consists of two components that are applied to a person within an interval of 21 days. It was developed by Russia's Gamaleya Centre and registered by the Russian government on 11 August 2020.